News

AgroSpheres and BASF Announce Major Strategic Partnership

AgroSpheres, a biotechnology leader in sustainable crop protection and crop health, and BASF, a global leader in agricultural solutions, are excited to announce their strategic partnership on a category defining novel bioinsecticide. This collaboration marks a significant step forward in sustainable agriculture solutions aimed at enhancing crop protection.

The companies are working together to develop biological crop protection products leveraging AgroSpheres AgriCell-powered biomolecules. Both companies are encouraged by the levels of efficacy that have been demonstrated at low dose rates to control key agricultural lepidopteran pests. Both companies are committed to working together to develop innovative and sustainable crop protection products that will increase the choices available to farmers to manage pests and support optimal productivity.

Payam Pourtaheri, CoFounder and CEO of AgroSpheres, stated, “Our partnership with BASF exemplifies the synergy that can be achieved when innovative biotech meets extensive agricultural expertise. The results of our bioinsecticide development are extremely promising, and we are eager to continue our work together to bring effective solutions to farmers worldwide.”

Ameer Shakeel, CoFounder and CTO of AgroSpheres, added, “This collaboration is a testament to our team’s ability to develop novel biomolecules, amplify them with the AgriCell and forge strategic partnerships to reach farmers around the world. We are proud to partner with BASF and are excited about the potential impact of our partnership.”

Both companies are committed to furthering their research and development efforts, with plans to accelerate the development of this product line and launch a pipeline powered by the AgriCell.

Stephanie Jensen, Vice President, Crop System Rice and Portfolio Solutions Insecticides and Seed Treatment, BASF Agricultural Solutions, concluded, “We are incredibly encouraged by the results we’ve achieved thus far and by the potential impact for our customers from this innovative technology. Moving forward, our focus remains on delivering a bioinsecticide that adds genuine value for farmers, promoting higher yields and healthier crops.”

Stefan Tresch, Head of New Technologies & BioSolutions at BASF Agricultural Solutions, remarked, “BASF is dedicated to developing innovative solutions that provide added benefit to our agricultural customers, and we believe in the unique value represented by the AgriCell platform. AgroSpheres has showcased some of the most promising biomolecules we’ve encountered. Our collaboration with AgroSpheres is a testament to the power of partnerships in driving innovation.”

Both AgroSpheres and BASF are dedicated to fostering a sustainable agricultural ecosystem, and this partnership is a crucial step in that journey.

 

Learn more here.

Recent News

09/17/2026

Rivanna Announces New CMS Procedure Code for Computer-aided Neuraxial Guidance

RIVANNA®, developer of AI-enabled clinical decision-support solutions, today announced that the Centers for Medicare & Medicaid Services (CMS) has established ICD-10-PCS code XEZU3HC, effective for inpatient discharges beginning October 1, 2026. The code identifies computer-aided intraprocedural navigation in the spinal canal using ultrasound imaging with continuous needle tracking via a percutaneous approach during neuraxial anesthesia.

09/17/2026

From Lab to Three Continents: Agrospheres and FMC Corporation Advance Bioinsecticide Pipeline into Global Field Trials

AgroSpheres, a biotechnology company pioneering breakthroughs in sustainable crop protection and FMC Corporation (NYSE: FMC), a global leader in agricultural sciences, today announced a significant advancement in its ongoing collaboration. Two proprietary RNA-based biomolecule candidates from AgroSpheres’ pipeline are now entering global field trial development, marking the transition from discovery into real-world testing across three

09/15/2026

Jazz Pharmaceuticals Completes Acquisition of Actio Biosciences

Jazz Pharmaceuticals plc (Nasdaq: JAZZ) (“Jazz” or the “Company”) today announced the successful completion of its acquisition of privately-held Actio Biosciences, Inc. (“Actio”) for $820 million upfront. Actio is now a wholly-owned subsidiary of Jazz. “ABS-1230 holds the promise of being a transformative, first-in-class therapy for individuals living with KCNT1-related epilepsy,” said Renee Gala, president and